成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Metabolic Enzyme/Protease Anti-infection Apoptosis GPCR/G Protein
  3. Cytochrome P450 Fungal Apoptosis Caspase Platelet-activating Factor Receptor (PAFR)
  4. Cedrol

Cedrol  (Synonyms: (+)-Cedrol; α-Cedrol)

目錄號(hào): HY-N2071 純度: ≥98.0%
COA 產(chǎn)品使用指南 技術(shù)支持

Cedrol 是一種有效的細(xì)胞色素 P-450(CYP) 酶競(jìng)爭(zhēng)性抑制劑。Cedrol 通過誘導(dǎo)細(xì)胞周期阻滯和 Caspase 依賴性凋亡 (apoptosis) 發(fā)揮抗癌的作用。Cedrol 作為中性粒細(xì)胞激動(dòng)劑，可使細(xì)胞對(duì) N-甲?；牡暮罄m(xù)刺激脫敏。Cedrol 通過抑制氧化應(yīng)激和炎癥來預(yù)防慢性收縮性損傷引起的神經(jīng)性疼痛。此外，Cedrol 還具有抗菌、預(yù)防脫發(fā)和抗焦慮的作用。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Cedrol Chemical Structure

Cedrol Chemical Structure

CAS No. : 77-53-2

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥110
In-stock
100 mg ￥100
In-stock
200 mg   詢價(jià)  
500 mg   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Cedrol:

MCE 顧客使用本產(chǎn)品發(fā)表的 1 篇科研文獻(xiàn)

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties[1][2][3][4][5][6][7].

IC50 & Target

CYP2

 

CYP3

 

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
CTX TNA2 IC50
238.3 μM
Compound: Ced
Cytotoxicity against rat CTX TNA2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against rat CTX TNA2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 32960603]
CTX TNA2 IC50
254.7 μM
Compound: Ced
Cytotoxicity against rat CTX TNA2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against rat CTX TNA2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 32960603]
CTX TNA2 IC50
279.9 μM
Compound: Ced
Cytotoxicity against rat CTX TNA2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against rat CTX TNA2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 32960603]
DBTRG-05MG IC50
101.5 μM
Compound: Ced
Cytotoxicity against human DBTRG-05MG cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human DBTRG-05MG cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 32960603]
DBTRG-05MG IC50
107.2 μM
Compound: Ced
Cytotoxicity against human DBTRG-05MG cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human DBTRG-05MG cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 32960603]
DBTRG-05MG IC50
118.7 μM
Compound: Ced
Cytotoxicity against human DBTRG-05MG cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human DBTRG-05MG cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 32960603]
RG2 IC50
107 μM
Compound: Ced
Cytotoxicity against rat RG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against rat RG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 32960603]
RG2 IC50
89.2 μM
Compound: Ced
Cytotoxicity against rat RG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against rat RG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 32960603]
RG2 IC50
93.3 μM
Compound: Ced
Cytotoxicity against rat RG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against rat RG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 32960603]
體外研究
(In Vitro)

Cedrol (0-450 μM；24-72 小時(shí)) 以劑量和時(shí)間依賴的方式抑制 HT-29 和 CT-26 細(xì)胞增殖，IC50 值分別為 138.91 和 92.46 μM[4]。
Cedrol (0-225 μM；0-48 小時(shí)) 在 HT-29 和 CT-26 細(xì)胞中可通過調(diào)節(jié)細(xì)胞周期調(diào)節(jié)因子 CDK4 和 cyclin D1 的表達(dá)，誘導(dǎo)細(xì)胞周期阻滯在 G0/G1 期，并通過外源性 (FasL/caspase-8) 和內(nèi)源性 (Bax/caspase-9) 途徑引發(fā)細(xì)胞凋亡[4]。
Cedrol (0-180 μM；48 小時(shí)) 與 5-FU (HY-90006) 聯(lián)合使用顯著降低 HT-29 細(xì)胞活率[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[4]

Cell Line: HT-29 and CT-26 cells
Concentration: 0, 14, 28, 56, 112, 225, and 450 μM
Incubation Time: 24, 48, and 72 h
Result: Inhibited the growth of cells in a dose- and time-dependent manner.

Western Blot Analysis[4]

Cell Line: HT-29 and CT-26 cells
Concentration: 180 μM;
0, 135, 180 and 225 μM
Incubation Time: 0, 6, 12, 24 and 48 h;
24 h
Result: Reduced the levels of CDK4 and cyclin D1.
Significantly increased the expression levels of FasL/cleaved-caspase-8, Bax/cleaved-caspase-9 and cleaved-caspase-3 in a time- and dose-dependent manner.
體內(nèi)研究
(In Vivo)

Cedrol (150 mg/kg；皮下注射；兩天一次；20 天) 在結(jié)直腸癌小鼠模型中具有抗腫瘤的作用[4]。
Cedrol (200-1600 mg/kg；腹腔注射；單劑量；測(cè)試前 30 分鐘) 在雌性小鼠中通過 5-羥色胺或多巴胺系統(tǒng)發(fā)揮抗焦慮作用[5]。
Cedrol (50-200 mg/kg; 局部涂抹； 27 天) 在 Cyclophosphamide (HY-17420) 誘導(dǎo)的小鼠脫發(fā)模型中具有預(yù)防脫發(fā)的作用[6]。
Cedrol (20-40 mg/kg；腹腔注射；一天一次；14 天) 在大鼠慢性收縮性損傷模型中可通過抑制氧化應(yīng)激和炎癥來緩解神經(jīng)性疼痛[7]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CT-26 cells treated BALB/c mice aged 10-12 weeks old (20-23 g)[4]
Dosage: 150 mg/kg
Administration: Subcutaneous injection (s.c.); once every 2 days for 10 times
Result: Suppressed the progression of colorectal cancer.
Improved the survival rate of animals.
Animal Model: Female ICR mice aged 5-6 weeks old[5]
Dosage: 200, 400, 800, 1200 and 1600 mg/kg
Administration: Intraperitoneal injection (i.p.); Single dose; 30 min prior to the test
Result: Exhibited anxiolytic activity on the female mice at dose of 1200-1600 mg/kg.
Increased the level of 5-hydroxytryptamine, decreased the level of dopamine.
Reduced the ratio of 5-hydroxyindoleacetic acid/5-hydroxytryptamine, increased the ratio of 3,4-dihydroxyphenyl acetic acid/dopamine.
Animal Model: Cyclophosphamide (HY-17420) treated adult female C57BL/6 mice aged 6 weeks (20 g)[6]
Dosage: 50, 100 and 200 mg/kg
Administration: Topical application; 27 days
Result: Inhibited alopecia in a dose-dependent manner, manifested mild alopecia with 40% suppression at a dose of 200 mg/kg on day 6 of the experiment.
Restored the hair follicles to its nearly normal modality at a dose of 200 mg/kg on day 15 of the experiment.
Promoted hair regrowth on day 11 of the experiment.
Animal Model: Adult male Wistar rats (220-270 g) with chronic constriction injury (CCI)[7]
Dosage: 20 and 40 mg/kg
Administration: Intraperitoneal injection (i.p.); once a day for 14 days
Result: Attenuated the CCI-induced mechanical and thermal hypersensitivity.
Increased the level of total thiol.
Reduced the levels of MDA.
Reduced the levels of TNF-α and IL-6.
分子量

222.37

Formula

C15H26O
CAS 號(hào)
性狀

固體

顏色

White to off-white

結(jié)構(gòu)分類
初始來源
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.
儲(chǔ)存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn)： 

DMSO 中的溶解度 : 110 mg/mL (494.67 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 4.4970 mL 22.4850 mL 44.9701 mL
5 mM 0.8994 mL 4.4970 mL 8.9940 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請(qǐng)依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.75 mg/mL (12.37 mM); 懸濁液; 超聲助溶

    此方案可獲得 2.75 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

    以 1 mL 工作液為例，取 100 μL 27.5 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請(qǐng)依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.75 mg/mL (12.37 mM); 澄清溶液

    此方案可獲得 ≥ 2.75 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 27.5 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

    2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只
由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量
請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料
參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.4970 mL 22.4850 mL 44.9701 mL 112.4252 mL
5 mM 0.8994 mL 4.4970 mL 8.9940 mL 22.4850 mL
10 mM 0.4497 mL 2.2485 mL 4.4970 mL 11.2425 mL
15 mM 0.2998 mL 1.4990 mL 2.9980 mL 7.4950 mL
20 mM 0.2249 mL 1.1243 mL 2.2485 mL 5.6213 mL
25 mM 0.1799 mL 0.8994 mL 1.7988 mL 4.4970 mL
30 mM 0.1499 mL 0.7495 mL 1.4990 mL 3.7475 mL
40 mM 0.1124 mL 0.5621 mL 1.1243 mL 2.8106 mL
50 mM 0.0899 mL 0.4497 mL 0.8994 mL 2.2485 mL
60 mM 0.0750 mL 0.3748 mL 0.7495 mL 1.8738 mL
80 mM 0.0562 mL 0.2811 mL 0.5621 mL 1.4053 mL
100 mM 0.0450 mL 0.2249 mL 0.4497 mL 1.1243 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Cedrol
目錄號(hào)：
HY-N2071
需求量：